{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:08:41Z","timestamp":1793164121135,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sleep-related symptoms, especially insomnia, are frequently reported by patients with Parkinson\u2019s disease (PD) and can markedly affect motor symptoms and impair patients\u2019 quality of life. Melatonin has been shown to improve sleep in PD patients. This pilot study aimed at evaluating the effects of a 3-month treatment with 2\u00a0mg melatonin prolonged-release (PR) on sleep and motor disability in PD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Twelve PD patients under stable antiparkinsonian treatment were enrolled in the study. Before treatment (T0), motor dysfunction was assessed with Unified Parkinson\u2019s Disease Rating Scale (UPDRS-III)\u00a0and sleep architecture with polysomnography. Subjective sleep quality was also\u00a0assessed through Pittsburgh Sleep Quality Index (PSQI) and daytime somnolence with Epworth Sleepiness Scale (ESS). Patients then started melatonin PR and all measures were repeated at the end of treatment after 3\u00a0months (T1).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sleep latency significantly decreased from T0 to T1, but no other significant differences were found in PSG parameters. Melatonin PR treatment significantly reduced the ESS scores from T0 to T1, while the PSQI scores presented a trend of improvement from T0 to T1. Motor dysfunction was not improved by melatonin PR, although there was a trend in decreasing UPDRS-III. Both clinical global improvement and patient clinical global impression documented an improvement in insomnia symptoms at T1.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These findings suggest that melatonin may improve sleep symptoms in PD patients, although further evidence is needed in larger controlled studies to confirm these results and explore the possible direct and indirect influence of sleep improvement on motor dysfunction.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10072-022-06111-x","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T15:04:36Z","timestamp":1652195076000},"page":"5355-5362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinson\u2019s disease: a preliminary evidence"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2845-1332","authenticated-orcid":false,"given":"Claudio","family":"Liguori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7005-2805","authenticated-orcid":false,"given":"Mariana","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Cerroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Ludovisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Biagio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Pierantozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"6111_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/0891988720964250","author":"D Santos-Garc\u00eda","year":"2020","unstructured":"Santos-Garc\u00eda D, Castro ES, de Deus FT et al (2020) Sleep problems are related to a worse quality of life and a greater non-motor symptoms burden in Parkinson\u2019s disease. J Geriatr Psychiatry Neurol. https:\/\/doi.org\/10.1177\/0891988720964250","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"6111_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.sleep.2021.02.036","volume":"81","author":"C Liguori","year":"2021","unstructured":"Liguori C, De Franco V, Cerroni R et al (2021) Sleep problems affect quality of life in Parkinson\u2019s disease along disease progression. Sleep Med 81:307\u2013311. https:\/\/doi.org\/10.1016\/j.sleep.2021.02.036","journal-title":"Sleep Med"},{"key":"6111_CR3","doi-asserted-by":"publisher","unstructured":"Comella CL (2006) Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview. J Neural Transm Suppl 349\u2013355.https:\/\/doi.org\/10.1007\/978-3-211-45295-0_53","DOI":"10.1007\/978-3-211-45295-0_53"},{"key":"6111_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3233\/JPD-202425","volume":"11","author":"K Suzuki","year":"2021","unstructured":"Suzuki K (2021) Current update on clinically relevant sleep issues in Parkinson\u2019s disease: a narrative review. J Parkinsons Dis 11:971\u2013992. https:\/\/doi.org\/10.3233\/JPD-202425","journal-title":"J Parkinsons Dis"},{"key":"6111_CR5","doi-asserted-by":"publisher","unstructured":"Suzuki K, Miyamoto M, Miyamoto T, Hirata K (2015) Parkinson\u2019s disease and sleep\/wake disturbances. Curr Neurol Neurosci Rep 15.https:\/\/doi.org\/10.1007\/s11910-015-0525-5","DOI":"10.1007\/s11910-015-0525-5"},{"key":"6111_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.smrv.2016.08.001","volume":"35","author":"LM Chahine","year":"2017","unstructured":"Chahine LM, Amara AW, Videnovic A (2017) A systematic review of the literature on disorders of sleep and wakefulness in Parkinson\u2019s disease from 2005 to 2015. Sleep Med Rev 35:33\u201350. https:\/\/doi.org\/10.1016\/j.smrv.2016.08.001","journal-title":"Sleep Med Rev"},{"key":"6111_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1474-4422(18)30127-3","volume":"17","author":"J Marinus","year":"2018","unstructured":"Marinus J, Zhu K, Marras C et al (2018) Risk factors for non-motor symptoms in Parkinson\u2019s disease. Lancet Neurol 17:559\u2013568. https:\/\/doi.org\/10.1016\/S1474-4422(18)30127-3","journal-title":"Lancet Neurol"},{"key":"6111_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/mdc3.12694","volume":"6","author":"P Martinez-Martin","year":"2019","unstructured":"Martinez-Martin P, Rizos AM, Wetmore JB et al (2019) Relationship of nocturnal sleep dysfunction and pain subtypes in Parkinson\u2019s disease. Mov Disord Clin Pract 6:57\u201364. https:\/\/doi.org\/10.1002\/mdc3.12694","journal-title":"Mov Disord Clin Pract"},{"key":"6111_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1212\/WNL.0000000000003540","volume":"88","author":"LK Tholfsen","year":"2017","unstructured":"Tholfsen LK, Larsen JP, Schulz J et al (2017) Changes in insomnia subtypes in early Parkinson disease. Neurology 88:352\u2013358. https:\/\/doi.org\/10.1212\/WNL.0000000000003540","journal-title":"Neurology"},{"key":"6111_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.sleep.2016.01.016","volume":"21","author":"M Pierantozzi","year":"2016","unstructured":"Pierantozzi M, Placidi F, Liguori C et al (2016) Rotigotine may improve sleep architecture in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med 21:140\u2013144. https:\/\/doi.org\/10.1016\/j.sleep.2016.01.016","journal-title":"Sleep Med"},{"key":"6111_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26:90\u201399","journal-title":"Mov Disord"},{"key":"6111_CR12","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/mds.23168","volume":"25","author":"M Menza","year":"2010","unstructured":"Menza M, Dobkin RDF, Marin H et al (2010) Treatment of insomnia in Parkinson\u2019s disease: a controlled trial of eszopiclone and placebo. Mov Disord 25:1708\u20131714. https:\/\/doi.org\/10.1002\/mds.23168","journal-title":"Mov Disord"},{"key":"6111_CR13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.parkreldis.2013.03.003","volume":"19","author":"S Rios Romenets","year":"2013","unstructured":"Rios Romenets S, Creti L, Fichten C et al (2013) Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson\u2019s disease - a randomized study. Park Relat Disord 19:670\u2013675. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.03.003","journal-title":"Park Relat Disord"},{"key":"6111_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.parkreldis.2020.03.029","volume":"75","author":"JH Ahn","year":"2020","unstructured":"Ahn JH, Kim M, Park S et al (2020) Prolonged-release melatonin in Parkinson\u2019s disease patients with a poor sleep quality: a randomized trial. Park Relat Disord 75:50\u201354. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.03.029","journal-title":"Park Relat Disord"},{"key":"6111_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.105878","volume":"195","author":"R Daneshvar Kakhaki","year":"2020","unstructured":"Daneshvar Kakhaki R, Ostadmohammadi V, Kouchaki E et al (2020) Melatonin supplementation and the effects on clinical and metabolic status in Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. Clin Neurol Neurosurg 195:105878. https:\/\/doi.org\/10.1016\/j.clineuro.2020.105878","journal-title":"Clin Neurol Neurosurg"},{"key":"6111_CR16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.lfs.2017.11.016","volume":"192","author":"R Paul","year":"2018","unstructured":"Paul R, Phukan BC, Justin Thenmozhi A et al (2018) Melatonin protects against behavioral deficits, dopamine loss and oxidative stress in homocysteine model of Parkinson\u2019s disease. Life Sci 192:238\u2013245. https:\/\/doi.org\/10.1016\/j.lfs.2017.11.016","journal-title":"Life Sci"},{"key":"6111_CR17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s11011-013-9416-0","volume":"28","author":"GG Ortiz","year":"2013","unstructured":"Ortiz GG, Pacheco-Mois\u00e9s FP, G\u00f3mez-Rodr\u00edguez VM et al (2013) Fish oil, melatonin and vitamin E attenuates midbrain cyclooxygenase-2 activity and oxidative stress after the administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Metab Brain Dis 28:705\u2013709. https:\/\/doi.org\/10.1007\/s11011-013-9416-0","journal-title":"Metab Brain Dis"},{"issue":"8","key":"6111_CR18","doi-asserted-by":"publisher","first-page":"e0183090","DOI":"10.1371\/journal.pone.0183090","volume":"12","author":"A L\u00f3pez","year":"2017","unstructured":"L\u00f3pez A, Ortiz F, Doerrier C et al (2017) Mitochondrial impairment and melatonin protection in parkinsonian mice do not depend of inducible or neuronal nitric oxide synthases. PLoS One 12(8):e0183090","journal-title":"PLoS One"},{"key":"6111_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/jpi.12212","volume":"58","author":"A Naskar","year":"2015","unstructured":"Naskar A, Prabhakar V, Singh R et al (2015) Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. J Pineal Res 58:262\u2013274. https:\/\/doi.org\/10.1111\/jpi.12212","journal-title":"J Pineal Res"},{"key":"6111_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1600-079X.2007.00510.x","volume":"44","author":"CH Lin","year":"2008","unstructured":"Lin CH, Huang JY, Ching CH, Chuang JI (2008) Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats. J Pineal Res 44:205\u2013213. https:\/\/doi.org\/10.1111\/j.1600-079X.2007.00510.x","journal-title":"J Pineal Res"},{"key":"6111_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.sleep.2005.04.004","volume":"6","author":"GA Dowling","year":"2005","unstructured":"Dowling GA, Mastick J, Colling E et al (2005) Melatonin for sleep disturbances in Parkinson\u2019s disease. Sleep Med 6:459\u2013466. https:\/\/doi.org\/10.1016\/j.sleep.2005.04.004","journal-title":"Sleep Med"},{"key":"6111_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00415-006-0390-x","volume":"254","author":"CAM Medeiros","year":"2007","unstructured":"Medeiros CAM, Carvalhedo De Bruin PF, Lopes LA et al (2007) Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson\u2019s disease: a randomized, double blind, placebo-controlled study. J Neurol 254:459\u2013464. https:\/\/doi.org\/10.1007\/s00415-006-0390-x","journal-title":"J Neurol"},{"key":"6111_CR23","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30:1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"key":"6111_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF, Monk TH et al (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193\u2013213","journal-title":"Psychiatry Res"},{"key":"6111_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427\u2013427. https:\/\/doi.org\/10.1212\/WNL.17.5.427","journal-title":"Neurology"},{"key":"6111_CR26","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord 25:2649\u20132653. https:\/\/doi.org\/10.1002\/mds.23429","journal-title":"Mov Disord"},{"key":"6111_CR27","first-page":"153","volume-title":"Recent developments in Parkinson\u2019s disease","author":"S Fahn","year":"1987","unstructured":"Fahn S, Elton R (1987) Unified Parkinson\u2019s Disease Rating Scale. In: Fahn S, Marsden C, Calne D, Goldstein M (eds) Recent developments in Parkinson\u2019s disease. MacMillan Healthcare Information, Florham Park, pp 153\u2013164"},{"key":"6111_CR28","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD (2007) The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 4:28\u201337","journal-title":"Psychiatry (Edgmont)"},{"key":"6111_CR29","unstructured":"Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, Rockville"},{"key":"6111_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/brb3.2336","volume":"11","author":"S Grigoriou","year":"2021","unstructured":"Grigoriou S, Mart\u00ednez-Mart\u00edn P, Ray Chaudhuri K et al (2021) Effects of safinamide on pain in patients with fluctuating Parkinson\u2019s disease. Brain Behav 11:1\u20139. https:\/\/doi.org\/10.1002\/brb3.2336","journal-title":"Brain Behav"},{"key":"6111_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci11020232","volume":"11","author":"E Pe\u00f1a","year":"2021","unstructured":"Pe\u00f1a E, Borru\u00e9 C, Mata M et al (2021) Impact of SAfinamide on depressive symptoms in parkinson\u2019s disease patients (SADness-PD Study): a multicenter retrospective study. Brain Sci 11:1\u201311. https:\/\/doi.org\/10.3390\/brainsci11020232","journal-title":"Brain Sci"},{"key":"6111_CR32","unstructured":"Iber C, Ancoli-Israel S, Chesson AL, Quan SF (2007) The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. American academy of sleep medicine Westchester"},{"key":"6111_CR33","doi-asserted-by":"publisher","first-page":"597","DOI":"10.5664\/jcsm.2172","volume":"08","author":"RB Berry","year":"2012","unstructured":"Berry RB, Budhiraja R, Gottlieb DJ et al (2012) Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. J Clin Sleep Med 08:597\u2013619. https:\/\/doi.org\/10.5664\/jcsm.2172","journal-title":"J Clin Sleep Med"},{"key":"6111_CR34","doi-asserted-by":"publisher","unstructured":"Curcio G, Tempesta D, Scarlata S et al (2013) Validity of the Italian version of the Pittsburgh Sleep Quality Index (PSQI). 511\u2013519. https:\/\/doi.org\/10.1007\/s10072-012-1085-y","DOI":"10.1007\/s10072-012-1085-y"},{"key":"6111_CR35","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/mds.23476","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kohnen R, H\u00f6gl B et al (2011) Parkinson\u2019s disease sleep scale\u2013validation of the revised version PDSS-2. Mov Disord 26:644\u2013652. https:\/\/doi.org\/10.1002\/mds.23476","journal-title":"Mov Disord"},{"key":"6111_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10072-015-2409-5","volume":"37","author":"D Arnaldi","year":"2016","unstructured":"Arnaldi D, Cordano C, De Carli F et al (2016) Parkinson\u2019s Disease Sleep Scale 2: application in an Italian population. Neurol Sci 37:283\u2013288. https:\/\/doi.org\/10.1007\/s10072-015-2409-5","journal-title":"Neurol Sci"},{"key":"6111_CR37","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540\u2013545. https:\/\/doi.org\/10.1093\/sleep\/14.6.540","journal-title":"Sleep"},{"key":"6111_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s100720300004","volume":"23","author":"L Vignatelli","year":"2003","unstructured":"Vignatelli L, Plazzi G, Barbato A et al (2003) Italian version of the Epworth sleepiness scale: external validity. Neurol Sci 23:295\u2013300. https:\/\/doi.org\/10.1007\/s100720300004","journal-title":"Neurol Sci"},{"key":"6111_CR39","unstructured":"IBM (2020) SPSS - Statistical Package for Social Sciences"},{"key":"6111_CR40","doi-asserted-by":"publisher","unstructured":"H\u00f6l BE, G\u00f3mez-Ar\u00e9valo G, Garc\u00eda S et al (1998) A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson\u2019s disease. Neurology 50:1332 LP\u20131339. https:\/\/doi.org\/10.1212\/WNL.50.5.1332","DOI":"10.1212\/WNL.50.5.1332"},{"key":"6111_CR41","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.parkreldis.2013.03.014","volume":"19","author":"MM van Gilst","year":"2013","unstructured":"van Gilst MM, Bloem BR, Overeem S (2013) \u201cSleep benefit\u201d in Parkinson\u2019s disease: a systematic review. Park Relat Disord 19:654\u2013659. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.03.014","journal-title":"Park Relat Disord"},{"key":"6111_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M et al (2019) Update on treatments for nonmotor symptoms of Parkinson\u2019s disease\u2014an evidence-based medicine review. Mov Disord 34:180\u2013198. https:\/\/doi.org\/10.1002\/mds.27602","journal-title":"Mov Disord"},{"key":"6111_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10571-019-00720-5","volume":"40","author":"OR Tamtaji","year":"2020","unstructured":"Tamtaji OR, Reiter RJ, Alipoor R et al (2020) Melatonin and Parkinson disease: current status and future perspectives for molecular mechanisms. Cell Mol Neurobiol 40:15\u201323. https:\/\/doi.org\/10.1007\/s10571-019-00720-5","journal-title":"Cell Mol Neurobiol"},{"key":"6111_CR44","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1365-2869.2007.00570.x","volume":"16","author":"P Hagell","year":"2007","unstructured":"Hagell P, Broman JE (2007) Measurement properties and hierarchical item structure of the Epworth sleepiness scale in Parkinson\u2019s disease. J Sleep Res 16:102\u2013109. https:\/\/doi.org\/10.1111\/j.1365-2869.2007.00570.x","journal-title":"J Sleep Res"},{"key":"6111_CR45","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1389-9457(03)00105-9","volume":"4","author":"S Kumar","year":"2003","unstructured":"Kumar S, Bhatia M, Behari M (2003) Excessive daytime sleepiness in Parkinson\u2019s disease as assessed by Epworth Sleepiness Scale (ESS). Sleep Med 4:339\u2013342. https:\/\/doi.org\/10.1016\/S1389-9457(03)00105-9","journal-title":"Sleep Med"},{"key":"6111_CR46","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1001\/jamaneurol.2013.6239","volume":"71","author":"A Videnovic","year":"2014","unstructured":"Videnovic A, Noble C, Reid KJ et al (2014) Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol 71:463\u2013469. https:\/\/doi.org\/10.1001\/jamaneurol.2013.6239","journal-title":"JAMA Neurol"},{"key":"6111_CR47","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaneurol.2018.0640","volume":"75","author":"E De Pablo-Fern\u00e1ndez","year":"2018","unstructured":"De Pablo-Fern\u00e1ndez E, Courtney R, Warner TT, Holton JL (2018) A histologic study of the circadian system in Parkinson disease, multiple system atrophy, and progressive supranuclear palsy. JAMA Neurol 75:1008\u20131012. https:\/\/doi.org\/10.1001\/jamaneurol.2018.0640","journal-title":"JAMA Neurol"},{"key":"6111_CR48","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s00415-018-09179-8","volume":"266","author":"C Liguori","year":"2019","unstructured":"Liguori C, Mercuri NB, Albanese M et al (2019) Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson\u2019s disease. J Neurol 266:636\u2013641. https:\/\/doi.org\/10.1007\/s00415-018-09179-8","journal-title":"J Neurol"},{"key":"6111_CR49","doi-asserted-by":"publisher","unstructured":"Zisapel N, Lemoine, Garfinkel D et al (2011) Prolonged-release melatonin for insomnia - an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag 301.https:\/\/doi.org\/10.2147\/tcrm.s23036","DOI":"10.2147\/tcrm.s23036"},{"key":"6111_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2021.688890","volume":"12","author":"L Palagini","year":"2021","unstructured":"Palagini L, Manni R, Aguglia E et al (2021) International expert opinions and recommendations on the use of melatonin in the treatment of insomnia and circadian sleep disturbances in adult neuropsychiatric disorders. Front Psychiatry 12:1\u201315. https:\/\/doi.org\/10.3389\/fpsyt.2021.688890","journal-title":"Front Psychiatry"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06111-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06111-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06111-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T03:30:32Z","timestamp":1661139032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06111-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["6111"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06111-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"assertion":[{"value":"7 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Open Access funding information has been added in the Funding Note.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the institutional review board or independent ethics committee at the study site.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent before study enrolment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}